HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study

doi:10.1016/j.ejca.2022.12.019

Chia Nan University of Pharmacy & Science Institutional Repository > 行政單位 > 456 > Item 310902800/34931

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34931

標題:	HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study
作者:	Chen, Po-Chuan Yeh, Yu-Min Chu, Chun-Ting Su, Pei-Fang Chiu, Pin-Hsuan Lin, Bo-Wen Chen, Shang-Hung Lin, Peng-Chan Lee, Chung-Ta Chen, Helen H. W. Chen, Chien-Chin
貢獻者:	Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg,Div Colorectal Surg Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Surg, Div Colorectal Surg Natl Cheng Kung Univ, Dept Stat Natl Cheng Kung Univ Hosp, Ctr Quantitat Sci, Clin Med Res Ctr Natl Hlth Res Inst, Natl Inst Canc Res Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Genom Med Natl Cheng Kung Univ, Coll Elect Engn & Comp Sci, Dept Comp Sci & Informat Engn Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pathol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Dept Biotechnol & Bioind Sci Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, PhD Program Translat Med
關鍵字:	HER2 amplification Colorectal cancer Brain metastasis Heterogeneity Propensity score matching
日期:	2023
上傳時間:	2024-12-25 11:05:50 (UTC+8)
出版者:	ELSEVIER SCI LTD
摘要:	Background: The association between human epidermal growth factor receptor -2 (HER2) amplification and brain metastasis (BM) in patients having colorectal cancer (CRC) has been suggested but not yet established. This study investigated the expression pat-terns of HER2, its association with BM, and its prognostic value in patients having CRC.Methods: We retrospectively identified 99 patients having metastatic CRC (mCRC) and BM (the BM cohort) and compared them with a cohort of 249 patients having mCRC and without BM (the stage IV cohort) by propensity score matching. Immunohistochemical studies of HER2 on all available paraffin-embedded tumour samples, either from the primary tumour, the metastasis (brain and/or extracranial sites) or both, were performed and analysed. HER2 fluorescent in situ hybridisation was applied when necessary. The expression of HER2 was compared and correlated with survival.Results: HER2 amplifications were detected in 16 (18.4%) of 87 and 9 (3.6%) of 249 patients who had specimens available in the BM and stage IV cohorts, respectively (P < .001). After propensity score matching, HER2 amplification was significantly associated with BM (odds ratio: 5.38, P = .003). HER2 heterogeneity was frequently observed not only at the single tumour level but also in paired tumour samples. A marginally significant longer survival since BM was found in patients having HER2-amplified mCRC than in those without (P = .07).Conclusions: HER2 amplification was significantly associated with BM in patients having mCRC and might have prognostic value for survival since BM. Given the heterogeneity of HER2 expression, the testing of HER2 status on available tissues from both primary and met-astatic tumours should be encouraged.(c) 2022 Elsevier Ltd. All rights reserved.
關聯:	European Journal of Cancer, v.181
显示于类别:	[行政單位] 456

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	5	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....